West Pharmaceutical Services (WST) Set to Announce Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) is set to announce its earnings results before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of $1.31 per share for the quarter. West Pharmaceutical Services has set its FY24 guidance at $7.50-7.75 EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, February 15th. The medical instruments supplier reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of $1.78 by $0.05. The firm had revenue of $732.00 million for the quarter, compared to the consensus estimate of $740.43 million. West Pharmaceutical Services had a net margin of 20.12% and a return on equity of 21.60%. The firm’s revenue was up 3.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.77 earnings per share. On average, analysts expect West Pharmaceutical Services to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

West Pharmaceutical Services Trading Up 0.9 %

Shares of NYSE:WST opened at $375.46 on Tuesday. The firm has a fifty day moving average of $377.94 and a two-hundred day moving average of $364.02. The company has a quick ratio of 2.24, a current ratio of 2.88 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services has a 12-month low of $310.42 and a 12-month high of $415.73. The firm has a market capitalization of $27.49 billion, a P/E ratio of 47.65, a price-to-earnings-growth ratio of 6.36 and a beta of 1.04.

West Pharmaceutical Services Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Wednesday, April 24th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Tuesday, April 23rd. This represents a $0.80 dividend on an annualized basis and a yield of 0.21%. West Pharmaceutical Services’s payout ratio is 10.15%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. UBS Group dropped their target price on West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating on the stock in a research report on Friday, February 16th. KeyCorp increased their price objective on West Pharmaceutical Services from $440.00 to $470.00 and gave the stock an “overweight” rating in a report on Tuesday, February 13th. Jefferies Financial Group upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and lifted their target price for the company from $323.00 to $536.00 in a research note on Wednesday, February 7th. Finally, StockNews.com downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $435.20.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, CAO Chad Winters sold 815 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $358.82, for a total transaction of $292,438.30. Following the completion of the sale, the chief accounting officer now owns 1,309 shares of the company’s stock, valued at $469,695.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other West Pharmaceutical Services news, CEO Eric Mark Green sold 64,132 shares of the business’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $359.85, for a total transaction of $23,077,900.20. Following the completion of the transaction, the chief executive officer now owns 152,908 shares of the company’s stock, valued at approximately $55,023,943.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Chad Winters sold 815 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $358.82, for a total value of $292,438.30. Following the completion of the sale, the chief accounting officer now directly owns 1,309 shares in the company, valued at $469,695.38. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 73,978 shares of company stock valued at $26,653,772. Corporate insiders own 0.53% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.